These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31203694)

  • 1. Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.
    Ortiz de Montellano PR
    Drug Metab Rev; 2019 May; 51(2):162-177. PubMed ID: 31203694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes.
    Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP
    Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene.
    Chan WK; Sui Z; Ortiz de Montellano PR
    Chem Res Toxicol; 1993; 6(1):38-45. PubMed ID: 8448348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds.
    Lin HL; Zhang H; Walker VJ; D'Agostino J; Hollenberg PF
    Drug Metab Dispos; 2017 Sep; 45(9):990-999. PubMed ID: 28698302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450BM-3 (CYP102): regiospecificity of oxidation of omega-unsaturated fatty acids and mechanism-based inactivation.
    Shirane N; Sui Z; Peterson JA; Ortiz de Montellano PR
    Biochemistry; 1993 Dec; 32(49):13732-41. PubMed ID: 8257708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based inactivation of cytochrome P450 2B6 by a novel terminal acetylene inhibitor.
    Fan PW; Gu C; Marsh SA; Stevens JC
    Drug Metab Dispos; 2003 Jan; 31(1):28-36. PubMed ID: 12485950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein.
    Blobaum AL; Kent UM; Alworth WL; Hollenberg PF
    Chem Res Toxicol; 2002 Dec; 15(12):1561-71. PubMed ID: 12482238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein.
    Lin HL; Hollenberg PF
    J Pharmacol Exp Ther; 2007 Apr; 321(1):276-87. PubMed ID: 17251390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytochrome P-450 active site. Regiospecificity of prosthetic heme alkylation by olefins and acetylenes.
    Kunze KL; Mangold BL; Wheeler C; Beilan HS; Ortiz de Montellano PR
    J Biol Chem; 1983 Apr; 258(7):4202-7. PubMed ID: 6833252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P450 active site architecture and reversibility: inactivation of cytochromes P450 2B4 and 2B4 T302A by tert-butyl acetylenes.
    Blobaum AL; Harris DL; Hollenberg PF
    Biochemistry; 2005 Mar; 44(10):3831-44. PubMed ID: 15751959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How is a metabolic intermediate formed in the mechanism-based inactivation of cytochrome P450 by using 1,1-dimethylhydrazine: hydrogen abstraction or nitrogen oxidation?
    Hirao H; Chuanprasit P; Cheong YY; Wang X
    Chemistry; 2013 Jun; 19(23):7361-9. PubMed ID: 23592585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suicide inhibitors of cytochrome P450 1A1 and P450 2B1.
    Hopkins NE; Foroozesh MK; Alworth WL
    Biochem Pharmacol; 1992 Aug; 44(4):787-96. PubMed ID: 1510726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A proton-shuttle mechanism mediated by the porphyrin in benzene hydroxylation by cytochrome p450 enzymes.
    de Visser SP; Shaik S
    J Am Chem Soc; 2003 Jun; 125(24):7413-24. PubMed ID: 12797816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,2,3-Thiadiazole: a novel heterocyclic heme ligand for the design of cytochrome P450 inhibitors.
    Babu BR; Vaz AD
    Biochemistry; 1997 Jun; 36(23):7209-16. PubMed ID: 9188722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation of a novel reversible cytochrome P450 spectral intermediate: role of threonine 303 in P450 2E1 inactivation.
    Blobaum AL; Lu Y; Kent UM; Wang S; Hollenberg PF
    Biochemistry; 2004 Sep; 43(38):11942-52. PubMed ID: 15379534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suicidal destruction of cytochrome p-450 by ethynyl substituted compounds.
    White IN
    Pharm Res; 1984 Jul; 1(4):141-8. PubMed ID: 24277281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reductive activation of 1,1-dichloro-1-fluoroethane (HCFC-141b) by phenobarbital- and pyridine-induced rat liver microsomal cytochrome P450.
    Tolando R; Ferrara R; Eldirdiri NI; Albores A; King LJ; Manno M
    Xenobiotica; 1996 Apr; 26(4):425-35. PubMed ID: 9173683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic activation of acetylenic substituents to derivatives in the rat causing the loss of hepatic cytochrome P-450 and haem.
    White IN
    Biochem J; 1978 Sep; 174(3):853-61. PubMed ID: 728091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes?
    Blobaum AL
    Drug Metab Dispos; 2006 Jan; 34(1):1-7. PubMed ID: 16369051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450.
    Ortiz de Montellano PR; Komives EA
    J Biol Chem; 1985 Mar; 260(6):3330-6. PubMed ID: 3972828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.